Add-ons appear healthy
At the outset of the quarantines, at least one market observer—yours truly—believed add-ons would hit the pause button after two torrid years of deal flow. The assumption: it was hard to imagine too many add-ons being done when existing portfolio companies had so many sudden issues of their own.